a 2023

Tracking CLL cells with aberrations in the TP53 gene using scRNA-seq in relapsed/refractory patients.

NAVRKALOVÁ, Veronika; Terézia KURUCOVÁ; Kamila RÉBLOVÁ; Michaela BOHÚNOVÁ; Karla PLEVOVÁ et. al.

Basic information

Original name

Tracking CLL cells with aberrations in the TP53 gene using scRNA-seq in relapsed/refractory patients.

Authors

NAVRKALOVÁ, Veronika; Terézia KURUCOVÁ; Kamila RÉBLOVÁ; Michaela BOHÚNOVÁ; Karla PLEVOVÁ; Michael DOUBEK; Jitka MALČÍKOVÁ; Šárka PAVLOVÁ; Jana KOTAŠKOVÁ and Šárka POSPÍŠILOVÁ

Edition

XX. International Workshop on CLL (iwCLL 2023), Boston, USA, 2023

Other information

Language

English

Type of outcome

Konferenční abstrakta

Country of publisher

United States of America

Confidentiality degree

is not subject to a state or trade secret

References:

URL

Organization

Středoevropský technologický institut – Repository – Repository

Keywords in English

TP53 gene aberrations; CCL; resistance

Links

LX22NPO5102, research and development project. MUNI/A/1224/2022, interní kód Repo. NU20-08-00314, research and development project.
Changed: 27/3/2024 04:12, RNDr. Daniel Jakubík

Abstract

V originále

TP53 gene aberrations (mutation and/or deletion 17p) are the most important adverse prognostic and predictive markers in CLL • Low-burden TP53 mutations are often detectable in CLL cells prior to the therapy and expand upon the selective pressure of chemoimmunotherapy • Other genomic alterations accompany aberrations in the TP53 gene • Bulk analysis (such as whole genome/exome sequencing or genomic array) cannot precisely determine the co-occurrence of abnormalities in individual cells • Expression profiles of cells bearing TP53 mutation are altered and may be distinguished from expression profiles of unaffected cells using single-cell RNA sequencing (scRNA-seq). We aimed to explore the possibility to identify and characterize populations of CLL cells resistant to treatment and causing refractoriness in samples from patients with disease relapse. We tried to trace back the refractory cells in samples prior to the therapy using scRNA-seq in patients with TP53 mutations
Displayed: 6/7/2025 15:06